Home / Health / Oxford-AstraZeneca Covid-19 vaccine shows immune response in older adults

Oxford-AstraZeneca Covid-19 vaccine shows immune response in older adults

The vaccine causes few side effects and provokes a response in T-cells that target the virus within 14 days of the first dose and a protective antibody response within 28 days of the booster dose

Coronavirus, vaccine, tests, covid, drugs, clinical trials

Premium

The results of Oxford’s phase 2 study show that the vaccine is better tolerated in older people and produces a similar immune response in old and young adults

James Paton & Suzi Ring | Bloomberg

2 min read Last Updated : Nov 19 2020 | 11:29 PM IST

The University of Oxford confirmed that the Covid-19 vaccine it’s developing with AstraZeneca produced strong immune responses in older adults in an early study, with key findings from the last phase of tests expected in the coming weeks.

The results, published Thursday in The Lancet medical journal, shed more light on preliminary data released in recent months showing the experimental shot generated an immune response in the elderly, who are at highest risk of severe illness.

“This is a very important step, because the big worry with any vaccine is that it doesn’t work so well in older people,” Richard Horton.

The Lancet’s

Topics : Coronavirus Coronavirus Vaccine AstraZeneca Oxford University Coronavirus Tests World Health Organization Health crisis

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in